KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Common Equity: 2016-2024

Historic Common Equity for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$109.5 million.

  • Amneal Pharmaceuticals' Common Equity fell 17.51% to -$110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.0 million, marking a year-over-year decrease of 17.51%. This contributed to the annual value of -$109.5 million for FY2024, which is 647.26% down from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Common Equity is -$109.5 million, which was down 647.26% from $20.0 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Common Equity registered a high of $367.0 million during FY2021, and its lowest value of -$109.5 million during FY2024.
  • Over the past 3 years, Amneal Pharmaceuticals' median Common Equity value was $20.0 million (recorded in 2023), while the average stood at $31.5 million.
  • In the last 5 years, Amneal Pharmaceuticals' Common Equity climbed by 6.39% in 2021 and then plummeted by 647.26% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Common Equity (Yearly) stood at $344.9 million in 2020, then rose by 6.39% to $367.0 million in 2021, then slumped by 49.87% to $184.0 million in 2022, then slumped by 89.12% to $20.0 million in 2023, then plummeted by 647.26% to -$109.5 million in 2024.